Success Metrics for Hepatitis C Elimination Among People Who Inject Drugs: A Scoping Review of Indicators in Harm Reduction
David S. Kremer, Pauline Elizabeth Gatmaytan, Michelle Amanda Rübel, Antoine Flahault, Jennifer Hasselgard-Rowe

TL;DR
This study reviews which metrics are used to track hepatitis C elimination among drug users, finding that prevalence and incidence are most commonly reported, while other important indicators are often ignored.
Contribution
The study identifies a gap in the use of diverse and standardized success metrics for hepatitis C elimination in harm reduction programs targeting people who inject drugs.
Findings
Prevalence and incidence are the most frequently reported indicators for hepatitis C among people who inject drugs.
Screening, treatment uptake, and treatment completion are rarely reported in systematic reviews.
Inconsistent measurement approaches and a lack of standardized frameworks were observed across all indicators.
Abstract
This study aimed to identify and synthesize the success metrics used to assess hepatitis C elimination among people who inject drugs (PWID) through harm reduction strategies. A scoping review was performed by searching across three databases to identify systematic reviews that discussed hepatitis C in PWID within the context of harm reduction. The studies were then analyzed for success metrics used to describe hepatitis C in PWID. The indicators used were prevalence, incidence, screening, treatment uptake, treatment completion, and sustained virologic response. A total of fourteen systematic reviews were included. The most frequently reported indicators were prevalence and incidence, addressed in eight/seven systematic reviews, respectively. In contrast, screening, treatment uptake, and treatment completion were less commonly reported, with only two reviews addressing screening and…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHepatitis C virus research · Hepatitis B Virus Studies · HIV, Drug Use, Sexual Risk
